Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Semimalignant ("pseudolymphomatous") cutaneous B-cell lymphomas

G Burg1, M H Schmid, E Küng

  • 1Department of Dermatology, University Hospital, Zürich, Switzerland.

Dermatologic Clinics
|April 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modified lung ultrasound score for improved monitoring of pARDS on ECMO, a case report.

BMC pediatrics·2025
Same author

High CXCL-16 levels correlate with symptomatic disease in lung transplant recipients with human cytomegalovirus replication in the allograft.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2014
Same author

New daily persistent headache in the paediatric population.

Cephalalgia : an international journal of headache·2009
Same author

Which triptan for which patient?

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2006
Same author

Survival and prognostic factors in patients with brain metastases from malignant melanoma.

Onkologie·2004
Same author

Subcutaneous infection with Mycobacterium abscessus in a renal transplant recipient.

Dermatology (Basel, Switzerland)·2004
Same journal

The Evidence Is In: Devices and Biologics Reshaping Modern Dermatology.

Dermatologic clinics·2026
Same journal

Energy-Based Devices for Body Contouring.

Dermatologic clinics·2026
Same journal

Microfocused Ultrasound with Visualization for Skin Tightening: Clinical Applications, Safety, and Technical Considerations.

Dermatologic clinics·2026
Same journal

Devices in Onychomycosis: A Status Update.

Dermatologic clinics·2026
Same journal

Acne Laser Devices in Dermatology.

Dermatologic clinics·2026
Same journal

Fractional Laser Therapy for Androgenetic Alopecia: Mechanisms, Clinical Evidence, and Practical Implementation.

Dermatologic clinics·2026
See all related articles

Semimalignant cutaneous B-cell lymphoma (SM-CBCL) is a distinct entity from malignant CBCL and B-cell pseudolymphoma. Differentiating these conditions is crucial for appropriate therapeutic approaches.

Area of Science:

  • Dermatology
  • Oncology
  • Pathology

Background:

  • Cutaneous B-cell lymphoproliferative infiltrates often originate from follicular center cells.
  • A subset of these infiltrates, termed semimalignant cutaneous B-cell lymphoma (SM-CBCL), exhibits a distinct clinical course.

Purpose of the Study:

  • To establish clinical, histologic, and phenotypical criteria for differentiating SM-CBCL from malignant cutaneous B-cell lymphoma (CBCL) and B-cell pseudolymphoma (PSL).

Main Methods:

  • Retrospective analysis of clinical, histological, and phenotypic data from 60 patients.
  • Inclusion of patients with CBCL (n=11), SM-CBCL (n=30), and PSL (n=19).
  • Evaluation of specific markers including CD21 positive dendritic reticulum cells and immunoglobulin light chain restriction.

Related Experiment Videos

Main Results:

  • SM-CBCL shows no tendency for extracutaneous dissemination or transformation into high-grade lymphomas, with preserved normal survival.
  • SM-CBCL differs from PSL by the impossibility of complete cure for disseminated skin lesions and the presence of follicular center formation with CD21+ cells and light chain restriction.
  • Malignant CBCL exhibits a rapidly progressive course and tendency for dissemination.

Conclusions:

  • Distinct criteria allow reliable differentiation between SM-CBCL, malignant CBCL, and PSL.
  • Accurate diagnosis is essential for guiding appropriate therapeutic strategies for these distinct B-cell lymphoproliferative disorders.